Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoadjuvant camrelizumab plus albumin paclitaxel and cisplatin in locally advanced oral squamous cell carcinoma: A phase II Clinical Trial

Next Previous
Trial Profile

Neoadjuvant camrelizumab plus albumin paclitaxel and cisplatin in locally advanced oral squamous cell carcinoma: A phase II Clinical Trial

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Cisplatin; Paclitaxel
  • Indications Mouth neoplasm; Squamous cell cancer; Tongue cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 10 Jul 2024 New trial record
  • 04 Jun 2024 Results (From Feb 1, 2023 to Jan 1, 2024) assessing the efficacy and safety of NAIC, consisting of 2 cycles of intravenous camrelizumab (200 mg), albumin paclitaxel and cisplatin administered every 3 weeks prior to radical surgery in LAOSCC patients, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top